Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer.

Diana M. Tacelosky, Amy E. Creecy, Sriram S. Shanmugavelandy, Jill P. Smith, David F. Claxton, James H. Adair, Mark Kester, Brian M. Barth

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) has emerged as an alternative modality for cancer treatment. PDT works by initiating damaging oxidation or redox-sensitive pathways to trigger cell death. PDT can also regulate tumor angiogenesis and modulate systemic antitumor immunity. The drawbacks to PDT--photosensitizer toxicity, a lack of selectivity and efficacy of photosensitizers, and a limited penetrance of light through deep tissues--are the same pitfalls associated with diagnostic imaging. Developments in the field of nanotechnology have generated novel platforms for optimizing the advantages while minimizing the disadvantages of PDT. Calcium phosphosilicate nanoparticles (CPSNPs) represent an optimal nano-system for both diagnostic imaging and PDT. In this review, we will discuss how CPSNPs can enhance optical agents and serve as selective, non-toxic, and functionally stable photosensitizers for PDT. We will also examine novel applications of CPSNPs and PDT for the treatment of leukemia to illustrate their potential utility in cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)275-285
Number of pages11
JournalDiscovery Medicine
Volume13
Issue number71
StatePublished - Apr 2012

Fingerprint

Photochemotherapy
Nanoparticles
Calcium
Photosensitizing Agents
Neoplasms
Diagnostic Imaging
Nanotechnology
Penetrance
Oxidation-Reduction
Immunity
Leukemia
Cell Death
Therapeutics
Light

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Tacelosky, D. M., Creecy, A. E., Shanmugavelandy, S. S., Smith, J. P., Claxton, D. F., Adair, J. H., ... Barth, B. M. (2012). Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer. Discovery Medicine, 13(71), 275-285.
Tacelosky, Diana M. ; Creecy, Amy E. ; Shanmugavelandy, Sriram S. ; Smith, Jill P. ; Claxton, David F. ; Adair, James H. ; Kester, Mark ; Barth, Brian M. / Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer. In: Discovery Medicine. 2012 ; Vol. 13, No. 71. pp. 275-285.
@article{5cfb02acf9b348f7832eee33b44478bc,
title = "Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer.",
abstract = "Photodynamic therapy (PDT) has emerged as an alternative modality for cancer treatment. PDT works by initiating damaging oxidation or redox-sensitive pathways to trigger cell death. PDT can also regulate tumor angiogenesis and modulate systemic antitumor immunity. The drawbacks to PDT--photosensitizer toxicity, a lack of selectivity and efficacy of photosensitizers, and a limited penetrance of light through deep tissues--are the same pitfalls associated with diagnostic imaging. Developments in the field of nanotechnology have generated novel platforms for optimizing the advantages while minimizing the disadvantages of PDT. Calcium phosphosilicate nanoparticles (CPSNPs) represent an optimal nano-system for both diagnostic imaging and PDT. In this review, we will discuss how CPSNPs can enhance optical agents and serve as selective, non-toxic, and functionally stable photosensitizers for PDT. We will also examine novel applications of CPSNPs and PDT for the treatment of leukemia to illustrate their potential utility in cancer therapeutics.",
author = "Tacelosky, {Diana M.} and Creecy, {Amy E.} and Shanmugavelandy, {Sriram S.} and Smith, {Jill P.} and Claxton, {David F.} and Adair, {James H.} and Mark Kester and Barth, {Brian M.}",
year = "2012",
month = "4",
language = "English (US)",
volume = "13",
pages = "275--285",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "71",

}

Tacelosky, DM, Creecy, AE, Shanmugavelandy, SS, Smith, JP, Claxton, DF, Adair, JH, Kester, M & Barth, BM 2012, 'Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer.', Discovery Medicine, vol. 13, no. 71, pp. 275-285.

Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer. / Tacelosky, Diana M.; Creecy, Amy E.; Shanmugavelandy, Sriram S.; Smith, Jill P.; Claxton, David F.; Adair, James H.; Kester, Mark; Barth, Brian M.

In: Discovery Medicine, Vol. 13, No. 71, 04.2012, p. 275-285.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer.

AU - Tacelosky, Diana M.

AU - Creecy, Amy E.

AU - Shanmugavelandy, Sriram S.

AU - Smith, Jill P.

AU - Claxton, David F.

AU - Adair, James H.

AU - Kester, Mark

AU - Barth, Brian M.

PY - 2012/4

Y1 - 2012/4

N2 - Photodynamic therapy (PDT) has emerged as an alternative modality for cancer treatment. PDT works by initiating damaging oxidation or redox-sensitive pathways to trigger cell death. PDT can also regulate tumor angiogenesis and modulate systemic antitumor immunity. The drawbacks to PDT--photosensitizer toxicity, a lack of selectivity and efficacy of photosensitizers, and a limited penetrance of light through deep tissues--are the same pitfalls associated with diagnostic imaging. Developments in the field of nanotechnology have generated novel platforms for optimizing the advantages while minimizing the disadvantages of PDT. Calcium phosphosilicate nanoparticles (CPSNPs) represent an optimal nano-system for both diagnostic imaging and PDT. In this review, we will discuss how CPSNPs can enhance optical agents and serve as selective, non-toxic, and functionally stable photosensitizers for PDT. We will also examine novel applications of CPSNPs and PDT for the treatment of leukemia to illustrate their potential utility in cancer therapeutics.

AB - Photodynamic therapy (PDT) has emerged as an alternative modality for cancer treatment. PDT works by initiating damaging oxidation or redox-sensitive pathways to trigger cell death. PDT can also regulate tumor angiogenesis and modulate systemic antitumor immunity. The drawbacks to PDT--photosensitizer toxicity, a lack of selectivity and efficacy of photosensitizers, and a limited penetrance of light through deep tissues--are the same pitfalls associated with diagnostic imaging. Developments in the field of nanotechnology have generated novel platforms for optimizing the advantages while minimizing the disadvantages of PDT. Calcium phosphosilicate nanoparticles (CPSNPs) represent an optimal nano-system for both diagnostic imaging and PDT. In this review, we will discuss how CPSNPs can enhance optical agents and serve as selective, non-toxic, and functionally stable photosensitizers for PDT. We will also examine novel applications of CPSNPs and PDT for the treatment of leukemia to illustrate their potential utility in cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84865407229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865407229&partnerID=8YFLogxK

M3 - Review article

C2 - 22541615

AN - SCOPUS:84865407229

VL - 13

SP - 275

EP - 285

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 71

ER -

Tacelosky DM, Creecy AE, Shanmugavelandy SS, Smith JP, Claxton DF, Adair JH et al. Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer. Discovery Medicine. 2012 Apr;13(71):275-285.